Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 9—September 2022
Research

Fulminant Transfusion-Associated Hepatitis E Virus Infection Despite Screening, England, 2016–2020

Heli HarvalaComments to Author , Claire Reynolds, Su Brailsford, and Katy Davison
Author affiliations: University College of London, London, UK (H. Harvala); NHS Blood and Transplant, London (H. Harvala, C. Reynolds, S. Brailsford, K. Davison); UK Health Security Agency, London (K. Davison)

Main Article

Table 2

Incidence of hepatitis E virus RNA positive samples and estimated risk for nondetection, with 7-day window period risk for apheresis and whole blood donors. England, March 2016–December 2020

Donation type, year Incidence, HEV RNA–positive samples/1 million donors Risk per 1 million if window period 7 days (95% CI)
Apheresis
2016 1,966.5 37.69 (24.15–56.07)
2017 1,532.6 29.37 (17.94–45.36)
2018 1,935.8 37.10 (23.77–55.20)
2019 1,241.5 23.79 (13.32–39.24)
2020
2,052.7
39.34 (25.21–58.53)
Whole blood
2016 2,401.9 46.03 (39.45–53.40)
2017 1,184.6 22.70 (20.03–25.63)
2018 1,344.6 25.77 (23.14–28.61)
2019 1,788.8 34.28 (31.21–37.58)
2020 1,614.9 30.95 (27.91–34.23)

Main Article

Page created: July 14, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external